Lundbeck is a Denmark-based pharmaceutical firm that focuses on the development and commercialization of central nervous system drugs including antidepressants, antipsychotics, and antiepileptic products... Show more
The Stochastic Oscillator for HLBBF moved out of overbought territory on February 02, 2026. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 29 similar instances where the indicator exited the overbought zone. In of the 29 cases the stock moved lower. This puts the odds of a downward move at .
The Momentum Indicator moved below the 0 level on February 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on HLBBF as a result. In of 30 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for HLBBF turned negative on February 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 26 similar instances when the indicator turned negative. In of the 26 cases the stock turned lower in the days that followed. This puts the odds of success at .
HLBBF moved below its 50-day moving average on February 02, 2026 date and that indicates a change from an upward trend to a downward trend.
The Aroon Indicator for HLBBF entered a downward trend on January 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
HLBBF may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. HLBBF’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.569) is normal, around the industry mean (29.792). P/E Ratio (12.232) is within average values for comparable stocks, (74.095). HLBBF's Projected Growth (PEG Ratio) (7.551) is very high in comparison to the industry average of (2.035). Dividend Yield (0.022) settles around the average of (0.029) among similar stocks. P/S Ratio (1.586) is also within normal values, averaging (116.680).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HLBBF’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock worse than average.
Industry PharmaceuticalsGeneric
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| PRPAX | 6.00 | 0.12 | +2.04% |
| PGIM Jennison Energy Infrastructure A | |||
| MPSSX | 16.96 | 0.09 | +0.53% |
| BNY Mellon Small Cap Multi-Strategy M | |||
| SVAYX | 27.37 | 0.03 | +0.11% |
| SEI Large Cap Value Y (SIMT) | |||
| AZNAX | 11.75 | -0.03 | -0.25% |
| Virtus Income & Growth A | |||
| RWEBX | 65.66 | -0.42 | -0.64% |
| American Funds Washington Mutual R2E | |||
A.I.dvisor tells us that HLBBF and HYEX have been poorly correlated (+21% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that HLBBF and HYEX's prices will move in lockstep.
| Ticker / NAME | Correlation To HLBBF | 1D Price Change % | ||
|---|---|---|---|---|
| HLBBF | 100% | N/A | ||
| HYEX - HLBBF | 21% Poorly correlated | -9.09% | ||
| HLUBF - HLBBF | 18% Poorly correlated | N/A | ||
| HLN - HLBBF | 10% Poorly correlated | -0.66% | ||
| HLNCF - HLBBF | 8% Poorly correlated | +0.87% | ||
| EAPIF - HLBBF | 0% Poorly correlated | N/A | ||
More | ||||
| Ticker / NAME | Correlation To HLBBF | 1D Price Change % |
|---|---|---|
| HLBBF | 100% | N/A |
| Pharmaceuticals: Generic industry (214 stocks) | -1% Poorly correlated | -0.69% |